Icos Corporation

Fred Hutchinson Cancer Center

Gilead Calistoga LLC

Other

State of Oregon

W Michael Gallatin

Rosemay Vazeux

Monica Van Der Vieren

Thomas P St John

Rejean L Idzerda

Patrick D Kilgannon

Robert Owen Lockerbie

Roger G Ulrich

Neill A Giese

Monique L Howard

Langdon Miller

Brian Lannutti

Thomas M Jahn

John D Scott

Vincent M Coghlan

Yvonne Lai

The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, 

Therapies for hematologic malignancies

The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, 

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated &ldquo;ICAM-R&rdquo;) and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Antibodies substances specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding reactions involving ICAM-R.

I-CAM related protein

The present invention relates to monoclonal antibodies immunospecific for &agr; integrin, and antibodies that compete with said antibodies for &agr; binding.

Monoclonal antibodies specific for integrin &agr;-d subunit

Methods to treat spinal cord injury using &agr; monoclonal antibodies are disclosed.

Methods of inhibiting locomotor damage following spinal cord injury with &agr; D-specific antibodies

Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;,are disclosed.

Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated 'ICAM-R') and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.

ICAM-related protein

The present invention provides compositions and methods useful for isolating calcineurin as well as inhibiting calcineurin activity. The compositions are peptides that contain regions that are homologous to calcineurin-binding regions of AKAP 79. Also provided are methods for determining if a cell contains a calcineurin-binding and PKA-binding anchoring protein that are useful for identifying additional proteins that bind both calcineurin and PKA. Another aspect of the present invention is methods for enhancing expression of interleukin 2 by T cells. Further provided are methods to identify proteins which interact with AKAP 79, and methods to identify inhibitors of AKAP 79 interaction with other proteins.

Modulators of anchoring protein function

Fusion proteins comprising ICAM-R polypeptides and immunoglobulin

Antibody substances that bind to a novel human intercellular adhesion molecule polypeptide (designated 'ICAM-R') and variants thereof are disclosed along with methods and materials producing and screening the same for desired functional and binding properties. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.

Antibody substances that bind to ICAM-related protein

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated 'ICAM-R') and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Antibodies and other binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.

Antibodies to ICAM-related protein

Therapeutic methods using antibodies to an adhesion receptor for high endothelial venules (HEV).

Methods of using CD44-specific antibodies

Modulators of protein kinase C phosphorylation of human intercellular adhesion molecule polypeptide (designated 'ICAM-R') are identified through novel methods.

Methods for identifying modulators of protein kinase C phosphorylation

DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated 'ICAM-R') and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R. Specifically, antibody substances which modulate the interaction between ICAM-R and ad/CD18 are provided.

Growing community of inventors

Mercer Island, WA, United States of America

W Michael Gallatin